Carboplatin + Paclitaxel (adult granulosa cell tumor, advanced/recurrent)
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.
| Composantes | DRUG-CARBOPLATIN DRUG-PACLITAXEL |
|---|
| ID | REG-CARBOPLATIN-PACLITAXEL-GCT |
|---|---|
| Type | Protocole thérapeutique |
| État | reviewed 2026-05-04 | pending_clinical_signoff |
| Maladies | Aucune déclaration |
| Sources | SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 |
Notes
Carboplatin + paclitaxel is widely used as first-line chemotherapy for advanced/recurrent adult granulosa cell tumor (AGCT), extrapolated from ovarian cancer chemotherapy practice. No large randomized trial specific to GCT. BEP (bleomycin-etoposide-cisplatin) is an alternative (especially in younger patients or when platinum-taxane sensitivity unknown). Response rates ~50–70% in recurrent disease. Surgery remains primary modality; chemo is for advanced/inoperable or chemotherapy-sensitive recurrence. Hormone-directed therapy (leuprolide, letrozole) is active in hormone receptor-positive GCT, especially for maintenance.
Utilisé par
Indication
IND-GRANULOSA-CELL-1L-CARBOPLATIN-PACLITAXEL- IND-GRANULOSA-CELL-1L-CARBOPLATIN-PACLITAXEL